Video Library

Bronchioloalveolar carcinoma (BAC) is an unusual subtype of lung cancer; medical oncologist Dr. Jack West reviews the evidence on the best systemic therapy to treat advanced, multifocal BAC.

Bronchioloalveolar carcinoma (BAC), also known as adenocarcinoma in situ, is an unusual subtype of lung cancer with its own appearance under a microscope and on imaging. Dr. Jack West introduces some of the basics of the unique features of BAC. Download PDF Transcript Transcript One of the unusual

Unfortunately, there is as much misinformation as good information about the unusual subtype of lung cancer known as bronchioloalveolar carcinoma (BAC) or adenocarcinoma in situ. Dr. Jack West reviews the top 5 myths. Download PDF Transcript Transcript One of the unusual subtypes of lung cancer is

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the use of single agent vs. doublet chemotherapy in elderly patients.

For our 5th video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD joined GRACE to discuss the most appropriate treatment for elderly patients with advanced NSCLC, and whether age alters the recommendations.

For our 7th video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD joined GRACE to discuss the best treatment for frail patients with advanced NSCLC.

Dr. Mojun Zhu joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community. In this video, Dr. Zhu discusses if immunotherapy can help frail patients with advanced NSCLC. ***** Zhu Mojun Zhu博士加入GRACE任客座教授，为普通话社区提供最新信息

GRACE is excited to bring you a new series on current updates in Melanoma Treatment Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma service at Memorial Sloan Kettering and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chiefof Melanoma service at Memorial Sloan Kettering and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma service at Memorial Sloan Kettering and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University